ProMIS Neurosciences, Inc. (PMN)
NASDAQ: PMN · Real-Time Price · USD
0.7549
+0.0594 (8.54%)
At close: Apr 1, 2025, 4:00 PM
0.7028
-0.0522 (-6.91%)
After-hours: Apr 1, 2025, 4:21 PM EDT
ProMIS Neurosciences Employees
As of December 31, 2023, ProMIS Neurosciences had 7 total employees, including 6 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
$396,982
Market Cap
24.68M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7 | 0 | - |
Dec 31, 2022 | 7 | 1 | 16.67% |
Dec 31, 2021 | 6 | 5 | 500.00% |
Dec 31, 2020 | 1 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
PMN News
- 1 day ago - ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights - GlobeNewsWire
- 8 days ago - ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference - GlobeNewsWire
- 19 days ago - ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting - GlobeNewsWire
- 21 days ago - ProMIS Neurosciences to Participate in the 37th Annual Roth Conference - GlobeNewsWire
- 5 weeks ago - ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences Issues Letter to Shareholders - GlobeNewsWire
- 4 months ago - ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights - GlobeNewsWire